艾瑞宁联合钙尔奇D治疗佳木斯地区老年性骨质疏松症临床观察

目的:探索艾瑞宁联合钙尔奇D治疗老年性骨质疏松症疗效。方法:佳木斯地区老年性骨质疏松症患者100例,随机法分为观察组及对照组各50例。观察组及对照组患者钙尔奇D口服治疗6个月,观察组联合给予艾瑞宁静脉滴注治疗6个月。治疗结束后进行视觉模拟疼痛评分、骨密度测量、治疗效果评定、药物不良反应率比较。结果:观察组患者中无效例数1例,有效例数36例,显效例数13例,临床总有效率98. 0%;对照组患者中无效例数14例,有效例数25例,显效例数11例,临床总有效率72. 0%。观察组及对照组治疗前骨密度(BMD)比较无显著差异(P 0. 05);观察组及对照组治疗后骨密度(BMD)比较有显著差异(P 0. 05)。观察组不良反应率(8. 00%)明显低于对照组(40. 00%),有显著差异(P 0. 05)。结论:艾瑞宁是一种安全、高效的中老年骨质疏松症临床治疗药物,老年性骨质疏松症艾瑞宁联合钙尔奇D治疗效果显著。     

补肾活血汤联合钙尔奇治疗绝经后原发性骨质疏松症的效果分析

目的:对绝经后原发性骨质疏松症患者予以补肾活血汤联合钙尔奇治疗,以此分析补肾活血汤联合钙尔奇治疗的临床效果。方法:选择绝经后原发性骨质疏松症患者(例数:200例、选择时间:2016年9月-2018年9月),随机分钙尔奇治疗(对照组)、补肾活血汤联合钙尔奇治疗(研究组)。对组间的临床治疗总有效率、骨密度指标进行对比分析。结果:研究组的临床治疗总有效率(98.00%)、骨密度指标(Ward’s、L1-4分别为:0.66±0.04g/cm3、0.92±0.07g/cm3)均高于对照组(临床治疗总有效率、Ward’s、L1-4分别为:78.00%、0.47±0.05g/cm3、0.76±0.04g/cm3),P0.05,差异性显著。结论:对绝经后原发性骨质疏松症患者应予以补肾活血汤联合钙尔奇治疗,可以有效增加患者骨密度和提高其临床治疗效果。     

鲑鱼降钙素注射液治疗原发性骨质疏松症82例效果观察

目的研究和探讨鲑鱼降钙素注射液治疗原发性骨质疏松症的临床疗效。方法选取了2010年1月—2012年1月入院治疗的164例原发性骨质疏松症患者为研究对象,分成治疗组和对照组各82例。治疗组给予鲑鱼降钙素注射液肌内注射,连续使用3个月,同时加服钙尔奇D;对照组给予单纯口服钙尔奇,连续使用3个月。结果治疗组治疗前骨密度为(0.716±0.241)g/cm2,治疗后骨密度为(0.796±0.121)g/cm2;对照组的82例患者,治疗前骨密度为(0.712±0.111)g/cm2,治疗后骨密度为(0.711±0.091)g/cm2。治疗前后比较,治疗组治疗后有明显改善,差异有统计学意义(P<0.05),而对照组治疗后无明显改善(P>0.05)。结论鲑鱼降钙素注射液治疗原发性骨质疏松症的临床疗效显著,是治疗原发性骨质疏松症安全有效的方法。     

阿托伐他汀联合降钙素对绝经期女性骨质疏松患者骨代谢指标的影响

目的探讨阿托伐他汀联合降钙素对绝经期女性骨质疏松患者骨代谢指标的影响。方法选取2017年2月-2018年2月来温州市中西医结合医院就医的绝经期骨质疏松症患者126例随机分为研究组和对照组各63例,对照组采用降钙素、钙尔奇D3片及骨化三醇胶丸进行治疗,研究组在对照组基础上采用阿托伐他汀进行治疗,以此观察两组患者治疗后骨密度、骨代谢指标以及并发症的发生率。结果治疗前两组腰椎L2-4、FN及Ward三角区BMD动态水平差异无统计学意义(P>0. 05);治疗后两组腰椎L2-4、FN及Ward三角区BMD动态水平均高于治疗前,且研究组高于对照组,差异均有统计学意义(P<0. 05)。治疗前两组AKP、OC、TP1NP以及PTH的水平差异无统计学意义(P>0. 05);治疗后两组AKP、OC、TP1NP以及PTH的水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0. 05)。治疗后研究组不良反应发生率4. 8%低于对照组的15. 9%,差异有统计学意义(P<0. 05)。结论采用阿托伐他汀与降钙素联合治疗绝经期OP女性患者能有效对其骨吸收进行抑制,对骨形成具有一定的促进作用,从而达到临床治疗目的。     

中西医结合治疗老年性骨质疏松症的临床疗效观察

目的：探讨中西医结合治疗老年性骨质疏松症的临床疗效。方法：选取本院2011年1月-2013年1月收治的120例老年性骨质疏松患者作为研究对象,按照随机数字表法将其均分为中西医结合组、中医组和西医组各40例,中西医结合组采取中药补肾活血方加西药钙尔奇D片以及阿法骨化醇片口服治疗,中医组仅采取补肾活血方治疗,西医组仅采取钙尔奇D片以及阿法骨化醇片口服治疗,比较三组患者治疗前后腰部及股骨颈等部位骨密度值变化情况及临床疗效。结果：中西医结合组治疗后腰椎2、腰椎3、腰椎4及股骨颈BMD值均明显高于中医组和西医组,差异均有统计学意义（P〈0.05）;中西医结合组治疗显效率和总有效率均明显高于中医组和西医组,差异均有统计学意义（P〈0.05）。结论：中西医结合治疗老年性骨质疏松症疗效显著,患者骨密度恢复情况良好,无不良反应,临床应用和推广价值较高。     

重组人甲状旁腺素(1-34)对绝经后妇女骨质疏松症治疗的有效性及对骨代谢标志物水平的影响

目的观察重组人甲状旁腺素(1-34)[rhPTH(1-34)]联合凯思立D(碳酸钙D3咀嚼片)对绝经后妇女骨质疏松症(PMOP)的骨密度和骨代谢标志物的影响。方法将57例PMOP患者随机分为试验组和对照组,试验组皮下注射rhPTH(1-34)20μg每日1次治疗,对照组肌肉注射降钙素20 IU每周1次治疗。2组均给予凯思立D1片/日(每片含元素钙500 mg和维生素D3 200 IU),试验时间6个月。测定每组治疗前后腰椎L2~4、股骨颈骨密度、骨代谢物血钙、血磷及骨源性碱性磷酸酶(BALP)、血清Ⅰ型胶原交联C末端肽(CTX)等指标。结果试验组腰椎BMD治疗后较治疗前明显增加,差异有统计学意义(P0.01);对照组腰椎骨密度治疗前后比较差异无统计学意义(P0.05),组间比较差异无统计学意义(P0.05)。而2组股骨颈骨密度的变化治疗前后比较均无统计学差异(P0.05),组间比较差异无统计学意义。试验组CTX和BALP治疗后均较治疗前明显上升(P0.01)。而对照组CTX治疗后比治疗前下降(P0.05),BALP在治疗后较治疗前明显升高(P0.01)。结论重组人甲状旁腺素(1-34)能明显增加腰椎骨密度,升高骨转换指标,治疗绝经后妇女骨质疏松症安全有效。     

绝经后骨质疏松症综合治疗效果分析

目的探讨绝经后骨质疏松症(PMOP)患者的综合治疗效果。方法按照随机数字表法选取2014年6月-2015年12月吉林大学第一医院74例PMOP患者分为常规治疗组和综合治疗组,每组37例。常规治疗组调节体内钙的代谢和促进钙的吸收(雌激素替代疗法、服用钙尔奇D、骨化三醇胶丸、阿仑膦酸钠及鼻喷鲑鱼降钙素喷鼻剂)、止痛治疗等。综合治疗组是在常规治疗组的基础上,配合健康教育、物理疗法和运动疗法,比较治疗前和治疗6个月后两组患者腰椎L2~4和股骨颈的骨密度及治疗6个月后两组患者的生活质量。结果治疗6个月后,两组患者的L2~4和股骨颈的骨密度均高于治疗前,且综合治疗组明显高于常规治疗组(P0.05);综合治疗组患者的生活质量明显高于常规治疗组,差异有统计学意义(P0.05)。结论综合治疗可有效提高绝经后骨质疏松症患者的骨密度、改善患者的生活质量。     

鲑鱼降钙素注射液在治疗老年骨质疏松症中的疗效

目的:观察鲑鱼降钙素注射液用于治疗老年骨质疏松症中的临床疗效.方法:选择我院收治的64例老年骨质疏松症患者作为观察对象,收治时间为2014年5月至2015年5月,将64例老年骨质疏松症患者随机分成两组,对照组32例患者采用钙剂进行治疗,实验组32例患者在对照组基础上加用鲑鱼降钙素注射液进行治疗,观察两组老年骨质疏松症患者治疗前后疼痛评分及治疗后的骨密度改善率.结果:实验组治疗后的骨密度改善率(87.50%)明显高于对照组(59.38%);且两组老年骨质疏松症患者治疗后疼痛评分存在显著差异(p<0.05),统计学有意义.结论:针对老年骨质疏松症患者采用鲑鱼降钙素注射液治疗的临床疗效较为显著,能帮助患者改善骨密度,减轻痛苦.     

中西医结合治疗绝经后骨质疏松症51例

目的　观察中西药配合治疗绝经后骨质疏松症临床疗效。方法　采用中医补肾壮骨佐以养血益气之法 ,以毓麟珠汤加减 ,同时配合服用钙尔奇D(每片含碳酸钙素 75 0mg维生素D6 0国际单位 )每日一片 ,2 4周为一疗程。结果　治疗前后的骨密度 (BMD)、雌二醇 (E2 )、睾酮 (T)、抗酒石酸盐酸性磷酸酶 (TRAP)各项指标间的差异有非常显著性 (P <0 .0 1)。结论　说明该项治疗对骨吸收的抑制和对骨形成有促进作用 ,能有效的防治骨质疏松症 ,其作用机制与类雌激素样作用相同【7】     

强化钙与维生素D牛奶对北京城区小学女生骨量的影响

目的 :　探讨饮用钙与维生素 D强化牛奶对北京城区青春前期女生骨量的影响。方法 :　为期一年设有对照的双盲干预研究。将来自北京市西城区 9所小学平均年龄为 1 0 .1岁的女生 75 7名随机分为对照组 (n=2 5 9) :保持日常饮食 ;实验 1组 (n=2 3 8) :除日常饮食外 ,饮用钙强化牛奶 1 3 7ml/d,含钙 2 3 3 mg;实验 2组 (n=2 6 0 ) :除日常饮食外 ,饮用钙和维生素 D强化牛奶 1 3 7ml/d,其中钙 2 3 3 mg,VD 3 .3μg。使用 2 4 h回顾法了解食物摄入、体力活动问卷了解体力活动情况 ,用双能 X线吸收仪 (DEXA)测定全身和前臂骨量。结果 :　与干预前相比 ,实验组 2全身骨矿物密度 (BMD)的增长率显著高于实验 1组和对照组 (9.6 %、8.3 %和 8.0 % ,P=0 .0 0 2 ) ;实验 1组、实验 2组桡骨远端 1 /3处 BMC和骨面积的增长率显著高于对照组 (BMC:1 3 .0 %、1 2 .9%和1 1 .7% ,P=0 .0 1 6 ;骨面积 :2 .3 %、2 .0 %和 1 .5 % ,P=0 .0 1 0 ) ;实验 1组前臂远端 1 /1 0处 BMC和BMD的增长率显著高于对照组 (P=0 .0 0 7)。结论 :　饮用钙与维生素 D强化牛奶能促进青春前期女生骨量的增长 ,饮用钙和维生素 D强化牛奶促进骨量增长的作用比饮用钙强化牛奶明显     

南昌地区成年男性骨密度现状及与吸烟关系的研究

目的 调查南昌地区健康成年男性骨密度,探讨吸烟与骨密度的关系.方法 采用法国MEDILINK公司生产的型号为OSTEOCORE2双能X线骨密度仪测量548例南昌地区健康成年男性正位腰椎(L2～L4)、左侧股骨颈及左前臂BMD,分析不同年龄组BMD及骨质疏松患病率变化.并根据吸烟指数进行分组,分析BMD与吸烟指数关系.结果 正位腰椎、股骨颈、前臂BMD峰值均出现在30～39岁年龄段,而后随年龄增加而下降,50岁以后降低更明显,骨质疏松患病率均随年龄增加而增加.吸烟指数与正位腰椎BMD呈负相关(r=-0.472,P＜0.01),与股骨颈、前臂BMD呈弱负相关(r值分别为-0.163和-0.135,P均＜0.05).结论 南昌地区男性BMD峰值出现在30～39岁年龄段,而后随年龄增加BMD下降,骨质疏松患病率增加.吸烟是骨质疏松的危险因素,为预防骨质疏松应尽早戒烟.     

2型糖尿病患者骨密度与相关因素分析

目的 探讨2型糖尿病患者骨质疏松的相关因素。方法 采用双能X射线骨密度仪测定120例2型糖尿病患者正位腰椎(L_1-4)、左侧股骨颈、左侧股骨粗隆及左侧股骨干骨密度,根据骨密度值分为骨量正常组、骨量减少组及骨质疏松组,观察各组年龄、病程、体质指数(BMI)、血清骨代谢及相关生化指标的变化,并对上述指标进行对比分析。结果 骨质疏松组在年龄、病程、BMI、血碱性磷酸酶(ALP)、Ⅰ型胶原氨基末端肽(SNTX)及血清25-羟维生素D (25-VitD)水平与正常组比较差异均有统计学意义(P < 0.05),骨量减少组与正常组比较仅年龄的差异有统计学意义(P < 0.05),其他指标无统计学差异(P > 0.05)。直线相关分析显示年龄、BMI及25-VitD与各部位骨密度均相关(P < 0.01或P < 0.05),病程与除腰椎外的其他部位骨密度呈负相关(P < 0.01),ALP与除股骨干之外的各部位骨密度呈负相关(P < 0.05),SCTX、SNTX分别与腰椎、股骨干骨密度呈负相关(P < 0.05)。结论 年龄、病程及低BMI是2型糖尿病患者骨质疏松的危险因素,检测血清25-VitD、ALP、SNTX和SCTX水平在一定程度上有助于判断个体是否易患骨质疏松。     

机械振动对绝经后骨质疏松患者骨密度影响

目的观察机械振动对绝经后骨质疏松患者骨密度(BMD)的影响。方法随机选择2014年2月~2015年10月就诊于广州军区广州总医院骨科医院康复理疗科及骨质疏松门诊的绝经后骨质疏松患者60例,分为阿仑膦酸钠组(ALN组)和机械振动组(WBV组),每组30例,两组均给予抗骨质疏松基础治疗,分别于入组时、治疗6个月后测定骨密度。结果WBV组治疗6个月后L1~L4、左股骨颈、左股骨上端、Ward's三角、左股骨大粗隆BMD较治疗前明显增加,其中Ward's三角BMD变化率最大(8.37%),差异有统计学意义(P0.05)。ALN组治疗6个月后L1~L4、左股骨颈、左股骨上端、左股骨大粗隆BMD较治疗前明显增加,其中L1~L4 BMD变化率最大(3.17%),差异有统计学意义(P0.05);而Ward's三角BMD虽有增加,但治疗前后相比,差异不具有统计学意义(P0.05)。治疗6个月后,WBV组左股骨(颈、上端、大粗隆)、Ward's三角的变化率均高于ALN组,而ALN组腰椎BMD变化率要高于WBV组。结论阿仑膦酸钠能明显增加腰椎骨密度;而机械振动对股骨、髋部骨密度提升明显,其中Ward's三角可以作为机械振动治疗指征和疗效判定指标;机械振动尤其适用于绝经后骨质疏松治疗。     

Effects of body mass index on bone mineral density in men

INTRODUCTION: A strong positive association between body mass index and bone mineral density is well defined in postmenopausal osteoporosis, but not in men. AIMS: The primary goal of the current research was to investigate this association in case of men. METHODS: According to WHO criteria (T-score below -1.0 at all measure site) seventy-two (mean age 55.7 +/- 0.99, range 38-78 yr normal density) healthy male with normal density were recruited. Exclusion criteria were the absence of any risk factors or signs of metabolic disease. Bone mineral measurements at the lumbar spine (L2-4) and femoral neck were performed by the dual-energy X-ray absorptiometry (DEXA, Lunar DPX-L, USA), bone mineral content of the non-dominant radius was measured with single photon absorptiometry (SPA, NK-364, Hungary). Participants were divided into three groups according to body mass index normal weight (18.5-24.9 kg/m2), moderate overweight (25-29.9 kg/m2) and obese subjects (> 30 kg/m2). RESULTS: Femur neck density was significantly lower in the normal weight than in the overweight counterparts (0.969 +/- 0.03 vs 1.062 +/- 0.02 p = 0.01). There was a strong positive association between BMI and femur neck BMD (r = 0.412 p < 0.001). Body mass was an independent predictor of femur neck bone mineral density (regression coefficients 0.382, p = 0.001). There was not correlation at the lumbar spine and the radius sites. CONCLUSION: Bone density at femur neck sites is lower in the normal weight men than in obese subjects, therefore the risk factors for proximal femur osteoporosis are higher in these cases. Prevention strategy is needed for men in the lowest quintile of body mass to prevent further decrease in BMD and reduce the risk of hip fracture.     

中老年男性雄激素部分缺乏患者骨密度测定的临床价值

目的 探讨中老年男性雄激素部分缺乏(PADAM)患者的骨密度(BMD)特点和骨质疏松的发生率.方法 采用双能X线骨密度仪对56例PADAM患者(PADAM组)和与之年龄、体重指数(BMI)相匹配的51例健康中老年人(对照组)进行腰椎及股骨颈等部位的BMD测定,采用MES-01S20肌肉功能分析仪测定肌肉分布和力学特性,并收集相关生化指标、激素水平及部分骨代谢指标进行多元逐步回归分析.结果 与对照组比较,PADAM组腰椎BMD无显著改变(P＞0.05),而股骨颈、Ward三角区和大转子的BMD显著降低(P＜0.01),且其抗骨折能力和下肢最大肌力显著降低(P＜0.01).PADAM组和对照组的骨量减少发生率分别为48.2%(27/56)和35.3%(18/51),骨质疏松患病率分别为30.4%(17/56)和21.6%(11/51),两组比较差异有统计学意义(P＜0.05).PADAM患者的腰椎BMD与BMI呈正相关,而股骨颈、Ward三角区、大转子的BMD与年龄呈负相关,与BMI、血清总睾酮呈正相关(P＜0.05).结论 PADAM患者的BMD及抗骨折能力明显降低,存在骨质疏松性骨折的潜在危险,加强PADAM患者骨折的预防和治疗有重要意义.

Abstract：

Objective To explore the characteristics of bone mineral density (BMD) and the incidence of osteoporosis in partial androgen deficiency in aging male (PADAM) patients.Methods Fifty-six PADAM patients (PADAM group) and 51 healthy persons (control group) were selected according to their age and body mass index (BMI),and measured their BMD in the second to fourth lumber and the neck of femur with the dual-energy C X-ray BMD measuring instrument.MES-01S20 muscle function analyzer was used to determinate the distribution and mechanical properties of muscle.The biochemical and bone metabolic markers and sexual hormones were collected and observed by multivariate stepwise regression analysis.Results Compared with control group,BMD significantly decreased in the Ward triangle,femoral neck and big rotor (P ＜ 0.01 ) and no significant change in lumbar in PADAM group (P ＞ 0.05 ),and the fracture strength of femoral neck (FS) and the lower-limb muscular strength (MS) also significantly decreased (P ＜ 0.01 ).The incidence of osteopenia were 48.2% (27/56) and 35.3% ( 18/51 ),osteoporosis were 30.4% (17/56) and 21.6% ( 11/51 ) respectively in PADAM group and control group.There was significant difference between two groups (P＜0.05).The BMD was positively correlated to BMI at the first to fourth lumber and negatively correlated to age,positively correlated to BMI and serum level of andrusol at the proximal left femur in the patients with PADAM.Conclusion BMD and the resistance to fracture aresignificantly lower in PADAM patients,and aging lower BMI and androgen deficiency are the risk factors of low BMD in PADAM patients.There is the potential of osteoporotic fracture risk,and it is important to strengthening the prevention and treatment of fractures in elderly PADAM patients.     

肌注醋酸甲羟孕酮对25～40岁妇女骨矿物质密度的影响及停药后的恢复

目的:观察应用醋酸甲羟基孕酮(DMPA)避孕对BMD的影响,分析停药后的恢复情况。方法:随机选择68例应用DMPA避孕的25～40岁女性,每3个月肌注DMPA 1次,用药24个月;同时选择59例25～40岁未应用激素避孕药的女性作为对照,其中用药组61例,对照组52例完成2年的停药观察。对两组患者用药及随访期间应用双能X光线吸收法测量腰椎和股骨颈BMD。结果:用药组用药2年后腰椎和股骨颈平均BMD从基础值(1.11±0.11)g/cm2和(0.91±0.10)g/cm2下降到(1.05±0.10)g/cm2和(0.86±0.10)g/cm2,分别下降了5.52%和6.35%;与对照组相比骨矿物质密度明显降低(P<0.001)。停药2年后,应用DMPA组平均BMD明显增高,虽然DMPA组腰椎和股骨颈BMD仍然低于其用药前基础水平的1.08%和2.30%,但与对照组相比,无统计学差异(P>0.05)。结论:年龄25～40岁女性应用DMPA导致骨矿物质密度降低,停止注射DMPA后,因使用DMPA所致BMD降低得以恢复。     

老年2型糖尿病合并骨质疏松症患者发病韵相关因素分析

目的探讨老年2型糖尿病合并骨质疏松症患者发病的相关危险因素。方法对本院106例老年2型糖尿病合并骨质疏松症患者的年龄、体重指数（BMI）、糖尿病病程与其骨密度（BMD）进行相关因素分析。结果老年2型糖尿病合并骨质疏松症患者中,80岁组的腰椎[（0．756±0．099）g／cm^2]、股骨颈[（0．658±0．111）g／cm^2]及Wards三角[（0．525±0．064）g／cm^2]BMD值较60岁组[（0．883±0．112）g／cm^2、（0．781±0．130）g／cm^2、（0．6274±0．118）g／cm^2]明显下降（P〈0．05）。低体重组（BMI≤20kg／m^2）的腰椎[（0．738±O．114）g／cm^2）]、股骨颈[（0．664±O．112）g／cm^2）]BMD值较正常体重组[（0．816±0．138）g／cm^2、（0．727±0．134）g／cm^2]明显下降（P〈0．05）。糖尿病病程〉10年组的腰椎[（0．743±O．122）g／cm^2]、股骨颈[（0．719±0．147）g／cm^2]BMD值较病程〈5年组[（0．886±0．132）g／cm^2、（0．792±0．122）g／cm^2]明显下降（P〈0．05）。骨密度与年龄、糖尿病病程呈负相关（P〈0．05）,与体重指数呈正相关（P〈0．05）。结论老年2型糖尿病合并骨质疏松症患者发病与高龄、低体重指数、糖尿病病程长的危险因素密切相关。     

Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception

The association between users of combined oral contraceptives and depot-medroxyprogesterone acetate (DMPA) for contraception and bone mineral density (BMD) has been controversial because of variations among studies. Like other studies, this cross-sectional study compares BMD in users of combined oral contraceptives and DMPA with that in nonusers. Unlike previous studies, we defined long-term use as >2 years, and we measured more bone sites than previous studies including lumbar spines, femurs, and forearms. The study group consisted of 59 women aged 30 years to 34 years who had been using combined oral contraceptives for 57.36 ± 27.02 months with a minimum period of 24 months, 34 women of the same age who had been using DMPA as contraceptive for 55.76 ± 35.31 months, and 62 women of the same age who had not used any steroid hormonal contraceptives for more than 6 months. BMD was measured by dual energy photon absorptiometer at lumbar spine 2–4, neck of femur, Ward’s triangle of femur, greater trochanter of femur, ultradistal radius, and distal ulnar, respectively. Age, body mass index, and lifestyles of both groups were matched with nonusers. Mean BMD at lumbar spine (L2–4) in the DMPA users was significantly lower than in the controls (1.031 ± 0.090 vs. 1.096 ± 0.116, P = 0.007). There were no significant differences in BMD values at bone sites other than lumbar spine between DMPA users and the controls. There were no significant differences in BMD values at all bone sites between combined oral contraceptives users and the controls. We conclude that combined oral contraceptives are not associated with changes in values of BMD, while DMPA is associated with decreased BMD only at lumbar spine. We comment that steroid hormonal contraceptives are safe to use for long-term contraception regarding bone mass effects.     

Relationship between Regular Green Tea Intake and Osteoporosis in Korean Postmenopausal Women: A Nationwide Study

Mixed results have been reported regarding whether habitual tea intake affects bone health. This study investigated the relationship between green tea intake and bone mineral density (BMD) in postmenopausal Korean women. We used data from the Korean National Health and Nutrition Examination Surveys from 2008 to 2011 and divided the participants into three groups according to their frequency of green tea intake over the past 12 months. BMD of the lumbar spine, total femur, and femur neck was measured using dual-energy X-ray absorptiometry. The odds ratios (ORs) and 95% confidence intervals (CIs) of osteoporosis and osteopenia according to green tea consumption were analyzed. Participants who did not consume green tea or consumed less than one cup per day were more likely to have osteopenia of the lumbar spine or femur than those who consumed it once to three times a day (OR 1.81 and 1.85, 95% CI, 1.20–2.71; and 1.23–2.77). Moreover, ORs for osteoporosis were 1.91 (95% CI 1.13–3.23) and 1.82 (95% CI 1.09–3.05) in non-consumers and consumers who drank less than one cup per day, respectively, compared with the reference group. These results support that green tea consumption may have benefits on bone health.     

中国四地区一般人群骨密度抽样研究

目的了解我国一般人群骨密度正常参考值.方法采用双能X线骨密度仪,对中国四地区20岁以上一般人群随机抽样2331例进行测量.结果确定男女不同年龄组腰椎及股骨近端骨密度正常参考值及骨峰值.结论进一步得出筛选治疗对象骨密度参考值及骨质疏松症诊断骨密度参考值.